EGFR and non-small cell lung carcinoma: In a previous study [40] conducted by Fan et al., acquired YES1 amplification was detected in five EGFR mutant NSCLC patients (three had the L858R mutation and two had the exon 19 deletion mutation) who were pre-treated with the EGFR-TKIs erlotinib or afatinib and had acquired resistance to EGFR-TKIs [40].